Expanded Access for Apixaban

Bristol-Myers Squibb (BMS)

Status

Treatments: Drug: Apixaban

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05187286

CV185-826

Details and patient eligibility

About

This is an expanded access designed to provide access to apixaban for eligible participants.

Sex: All

Ages: 28 days to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pediatric patients with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention
• Previously participated in the CV185-362 study and was on apixaban for 1 year or until treatment was no longer required

Exclusion criteria

• Weight less than 5 kg or greater than 35 kg

Other inclusion/exclusion criteria apply